| 2020 |
Söreskog E, Ström O, Spångéus A, Åkesson KE, Borgström F, Banefelt J, Toth E, Libanati C, Charokopou M. Risk of major osteoporotic fracture after first, second and third fracture in Swedish women aged 50 years and older. Bone. May 2020;134:115286. |
2 |
0 |
| 2021 |
Costa S, Fairfield H, Farrell M, Murphy CS, Soucy A, Vary C, Holdsworth G, Reagan MR. Sclerostin antibody increases trabecular bone and bone mechanical properties by increasing osteoblast activity damaged by whole-body irradiation in mice. Bone. June 2021;147:115918. |
1 |
1 |
| 2021 |
Morrell AE, Robinson ST, Ke HZ, Holdsworth G, Guo XE. Osteocyte mechanosensing following short-term and long-term treatment with sclerostin antibody. Bone. August 2021;149:115967. |
0 |
0 |
| 2022 |
Geusens P, Feldman R, Oates M, Thomas T, Makras P, Jakob F, Langdahl B, Wang Z, Rojeski M, Libanati C. Romosozumab reduces incidence of new vertebral fractures across severity grades among postmenopausal women with osteoporosis. Bone. January 2022;154:116209. |
0 |
0 |
| 2023 |
Skjødt MK, Nicolaes J, Smith CD, Libanati C, Cooper C, Olsen KR, Abrahamsen B. Healthcare costs associated with opportunistically identifiable vertebral fractures. Bone. October 2023;175:116831. |
0 |
0 |
| 2017 |
Kim SW, Lu Y, Williams EA, Lai F, Lee JY, Enishi T, Balani DH, Ominsky MS, Ke HZ, Kronenberg HM, Wein MN. Sclerostin antibody administration converts bone lining cells into active osteoblasts. J Bone Miner Res. May 2017;32(5):892-901. |
18 |
16 |
| 2018 |
McClung MR, Brown JP, Diez‐Perez A, Resch H, Caminis J, Meisner P, Bolognese MA, Goemaere S, Bone HG, Zanchetta JR, Maddox J, Bray S, Grauer A. Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double‐blind, phase 2, parallel group study. J Bone Miner Res. August 2018;33(8):1397-1406. |
18 |
16 |
| 2019 |
Ferrari S, Libanati C, Lin CJF, Brown JP, Cosman F, Czerwiński E, de Gregόrio LH, Malouf-Sierra J, Reginster J-Y, Wang A, Wagman RB, Lewiecki EM. Relationship between bone mineral density T-score and nonvertebral fracture risk over 10 years of denosumab treatment. J Bone Miner Res. June 2019;34(6):1033-1040. |
12 |
9 |
| 2020 |
Toth E, Banefelt J, Åkesson K, Spångeus A, Ortsäter G, Libanati C. History of previous fracture and imminent fracture risk in Swedish women aged 55 to 90 years presenting with a fragility fracture. J Bone Miner Res. May 2020;35(5):861-868. |
3 |
3 |
| 2020 |
Cosman F, Lewiecki EM, Ebeling PR, Hesse E, Napoli N, Matsumoto T, Crittenden DB, Rojeski M, Yang W, Libanati C, Ferrari S. T‐score as an indicator of fracture risk during treatment with romosozumab or alendronate in the ARCH trial. J Bone Miner Res. July 2020;35(7):1333-1342. |
1 |
1 |
| 2021 |
Holdsworth G, Staley JR, Hall P, van Koeverden I, Vangjeli C, Okoye R, Boyce RW, Turk JR, Armstrong M, Wolfreys A, Pasterkamp G. Sclerostin downregulation globally by naturally occurring genetic variants, or locally in atherosclerotic plaques, does not associate with cardiovascular events in humans. J Bone Miner Res. July 2021;36(7):1326-1339. |
1 |
1 |
| 2022 |
Eriksen EF, Chapurlat R, Boyce RW, Shi Y, Brown JP, Horlait S, Betah D, Libanati C, Chavassieux P. Modeling-based bone formation after 2 months of romosozumab treatment: results from the FRAME clinical trial. J Bone Miner Res. January 2022;37(1):36-40. |
1 |
1 |
| 2022 |
Banefelt J, Timoshanko J, Söreskog E, Ortsäter G, Moayyeri A, Åkesson KE, Spångéus A, Libanati C. Total hip bone mineral density as an indicator of fracture risk in bisphosphonate-treated patients in a real-world setting. J Bone Miner Res. January 2022;37(1):52-58. |
0 |
0 |
| 2022 |
Poole KES, Treece GM, Pearson RA, Gee AH, Bolognese MA, Brown JP, Goemaere S, Grauer A, Hanley DA, Mautalen C, Recknor C, Yang Y-C, Rojeski M, Libanati C, Whitmarsh T. Romosozumab enhances vertebral bone structure in women with low bone density. J Bone Miner Res. February 2022;37(2):256-264. |
1 |
1 |
| 2022 |
Thomas T, Tubach F, Bizouard G, Crochard A, Maurel F, Perrin L, Collin C, Roux C, Paccou J. The economic burden of severe osteoporotic fractures in the French healthcare database: the FRACTOS study. J Bone Miner Res. October 2022;37(10):1811-1822. |
1 |
1 |
| 2022 |
Pineda-Moncusí M, El-Hussein L, Delmestri A, Cooper C, Moayyeri A, Libanati C, Toth E, Prieto-Alhambra D, Khalid S. Estimating the incidence and key risk factors of cardiovascular disease in patients at high risk of imminent fracture using routinely collected real-world data from the UK. J Bone Miner Res. October 2022;37(10):1986-1996. |
0 |
0 |
| 2023 |
Nicolaes J, Skjødt MK, Raeymaeckers S, Smith CD, Abrahamsen B, Fuerst T, Debois M, Vandermeulen D, Libanati C. Towards improved identification of vertebral fractures in routine computed tomography (CT) scans: development and external validation of a machine learning algorithm. J Bone Miner Res. December 2023;38(12):1856-1866. |
0 |
0 |
| 2016 |
Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CAF, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A. Romosozumab treatment in postmenopausal women with osteoporosis. NEJM. October 20, 2016;375(16):1532-1543. |
87 |
71 |
| 2017 |
Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A. Romosozumab or alendronate for fracture prevention in women with osteoporosis. NEJM. October 12, 2017;377(15):1417-1427. |
73 |
60 |
| 2020 |
Lau EMC, Dinavahi R, Woo YC, Wu C-H, Guan J, Maddox J, Tolman C, Yang W, Shin CS. Romosozumab or alendronate for fracture prevention in East Asian patients: a subanalysis of the phase III, randomized ARCH study. Osteoporos Int. April 2020;31(4):677-685. |
2 |
2 |
| 2020 |
Skjødt MK, Khalid S, Ernst M, Rubin KH, Martinez-Laguna D, Delmestri A, Javaid MK, Cooper C, Libanati C, Toth E, Abrahamsen B, Prieto-Alhambra D. Secular trends in the initiation of therapy in secondary fracture prevention in Europe: a multi-national cohort study including data from Denmark, Catalonia, and the United Kingdom. Osteoporos Int. August 2020;31(8):1535-1544. |
2 |
0 |
| 2020 |
McClung MR, Bolognese MA, Brown JP, Reginster J-Y, Langdahl BL, Maddox J, Shi Y, Rojeski M, Meisner PD, Grauer A. A single dose of zoledronate preserves bone mineral density for up to 2 years after a second course of romosozumab. Osteoporos Int. November 2020;31(11):2231-2241. |
1 |
1 |
| 2020 |
Thomas T, Casado E, Geusens P, Lems WF, Timoshanko J, Taylor D, Hofbauer LC. Is a treat-to-target strategy in osteoporosis applicable in clinical practice? consensus among a panel of European experts. Osteoporos Int. December 2020;31(12):2303-2311. |
3 |
3 |
| 2021 |
Söreskog E, Lindberg I, Kanis JA, Åkesson KE, Willems D, Lorentzon M, Ström O, Berling P, Borgström F. Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden. Osteoporos Int. March 2021;32(3):585-594. |
0 |
0 |